Related Experiment Video
Updated: May 11, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Transcatheter aortic valve replacement: an update
Sharif A Halim1, Todd L Kiefer, G Chad Hughes
1Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA. sharif.halim@duke.edu
Insights
Transcatheter aortic valve replacement offers a significant survival benefit for patients with severe aortic stenosis who are ineligible for surgery. This minimally invasive approach is a crucial advancement in treating this common heart condition.
Area of Science:
- Cardiology
- Interventional Cardiology
- Geriatric Medicine
Background:
- Aortic stenosis is a prevalent valvular heart disease, particularly in older adults, leading to significant morbidity and mortality.
- Symptomatic severe aortic stenosis carries a poor prognosis, with high mortality rates if left untreated.
- Many elderly patients with aortic stenosis are poor surgical candidates, limiting treatment options.
Purpose of the Study:
- To review the current state of transcatheter aortic valve replacement (TAVR) technology.
- To discuss patient selection, procedural considerations, and potential complications associated with TAVR.
- To explore the future directions of transcatheter heart valves in managing aortic stenosis.
Main Methods:
- Review of existing literature and clinical trial data on transcatheter aortic valve replacement.
- Analysis of outcomes from studies comparing TAVR with medical therapy and surgical options.
- Discussion of procedural techniques, imaging, and patient management strategies.
Main Results:
- Transcatheter aortic valve replacement has demonstrated a significant mortality benefit in high-risk patients compared to medical management.
- The Sapien valve (PARTNER cohort B) showed a 20% absolute mortality reduction at one year in this patient group.
- TAVR is an established alternative for patients with prohibitive surgical risk.
Conclusions:
- Transcatheter aortic valve replacement is a safe and effective treatment for severe aortic stenosis in patients unsuitable for open-heart surgery.
- Careful patient selection and procedural planning are essential for optimal TAVR outcomes.
- Continued advancements in TAVR technology promise expanded applications in valvular heart disease management.
Abstract:
Aortic stenosis affects many people worldwide with a significant impact on morbidity and mortality with uncorrected, symptomatic aortic valve stenosis carrying mortality of 50% at one year. Degenerative calcific pathology, the most common cause of aortic stenosis, increases in prevalence with age; estimated prevalence of 5% in individuals over 75 years of age. Despite the malignant prognosis without valve replacement, many patients are not offered surgery due to advanced age and co-existing medical conditions; reported to be a third of symptomatic patients. In the last several years, transcatheter aortic valve replacement has emerged as an alternative treatment in patients with high or prohibitive open surgical risk. The PARTNER cohort B data, employing the Sapien valve, demonstrated a 20% absolute mortality benefit at one year compared with medical therapy. In this review, we provide an update of this technology and discuss patient selection, procedural planning, complications, and look toward the future of transcatheter heart valves in the treatment of aortic stenosis.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Aortic Regurgitation I: Introduction
Aortic Regurgitation IV: Nursing Management
Cardiac Catheterization I: Pre-Procedure Overview
Atherosclerosis III: Management
Mitral Stenosis III: Medical Management